Yew

Introduction Overview

Generic Name

Yew

Brand Name

Dosage Form

Plant material (needles, bark, leaves), no approved pharmaceutical dosage forms

Drug Class

Toxic plant containing cardiotoxic taxane alkaloids

Pharmacokinetics

Absorption:
Absorption of taxane alkaloids from yew occurs rapidly following ingestion of plant material such as needles or leaves. The phytochemicals, particularly taxines, are readily absorbed from the gastrointestinal tract due to their alkaloid structure, leading to early onset of toxic symptoms including dizziness, dry mouth, and abdominal cramping. However, no formal pharmacokinetic studies in humans exist due to the toxicity and lack of approved therapeutic uses of crude yew preparations.

Distribution:
Following absorption, taxine alkaloids distribute extensively throughout the body with notable affinity for cardiac tissue. Taxine compounds, including taxine B, concentrate in myocardial cells where they exert their toxic effects by disrupting ion channel function. Animal studies and clinical case reports have documented central nervous system involvement manifested by mydriasis and seizures, supporting CNS penetration of certain plant alkaloids. The distribution into milk is high, raising concerns about exposure during lactation.

Metabolism:
Metabolic pathways of yew alkaloids in humans are not fully characterized. In animal studies, taxanes undergo hepatic metabolism, involving cytochrome P450 enzymes, leading to various metabolites. The toxicity of parent compounds and metabolites remains significant. Because of the high toxicity and the absence of therapeutic dosing, detailed metabolic profiling has not been pursued clinically. Secondary metabolites from microbial endophytes within Taxus species may contribute to some antibacterial activities observed in vitro.

Elimination:
Elimination of yew components, including taxines, is primarily via hepatic and renal pathways, although the rate and extent are not fully elucidated. Due to the plant's toxicity, repeated ingestion or accumulation can result in lethal systemic levels. In documented poisoning cases, toxic alkaloid blood concentrations correlate with fatal outcomes. The clearance mechanisms appear insufficient to prevent cardiac and neurological toxicity once systemic absorption is established, necessitating intensive supportive care for poisoning episodes.

Dosage Forms

Available Dosage Forms:
- No standardized pharmaceutical formulations exist due to the toxicity of crude yew plant parts.
- Plant materials include needles, bark, leaves, and seeds with toxic taxane alkaloids.

Dosages for Adults and Adolescents:
- No approved therapeutic dosages available.
- Lethal dose thresholds: 0.6 to 1.3 grams of leaves/kg body weight (approximately 3 to 6.5 mg taxine/kg body weight) in humans.
- Adult lethal dose estimated at approximately 50 grams of yew needles (approximately 250 mg taxine alkaloids).

Specific Patient Populations:
- Use is contraindicated in pregnancy and lactation due to embryotoxicity and high concentration of alkaloids in breast milk observed in animal studies.
- No safety or efficacy data exist for pediatric populations; exposures may lead to severe poisoning.
- Patients with cardiovascular compromise are at increased risk of fatal outcomes due to taxine-induced cardiotoxicity.

Clinical Guidelines:
- Crude preparations of yew should not be administered therapeutically due to cardiotoxic risks.
- No clinical dosing recommendations; all usage is limited to experimental or traditional knowledge without medical endorsement.

Mechanism Of Action

Yew plants contain various toxic taxane alkaloids, with taxine B being the primary mediator of toxicity. Taxine alkaloids exert potent cardiotoxic effects by directly blocking sodium and calcium ion channels in cardiac myocytes. This blockade disrupts normal cardiac electrophysiology, leading to bradycardia, hypotension, ventricular tachyarrhythmias, and ultimately cardiac failure. Unlike chemotherapeutic taxanes used clinically, taxines are not intended for therapeutic use and are responsible for the plant's high toxicity profile.

At a molecular level, taxine alkaloids inhibit the influx of sodium and calcium ions during cardiac action potentials, interfering with depolarization and conduction through the atrioventricular node and myocardium. This results in negative chronotropic and inotropic effects, conduction abnormalities, and a predisposition to arrhythmias. These effects are highly resistant to standard antiarrhythmic therapies, posing challenges to clinical management of poisoning.

Clinical studies and case reports demonstrate that ingestion of yew leads to rapid onset of gastrointestinal, neurological, and cardiovascular symptoms due to the systemic distribution of these alkaloids. The red aril (fleshy seed covering) is non-toxic, but the remaining plant parts (needles, bark, leaves) contain concentrations of taxines sufficient to cause fatal toxicity. Digitoxin-specific antibody fragments have been observed to improve cardiac conduction abnormalities in cases, though treatment is primarily supportive.

Comparatively, chemotherapeutic taxanes such as docetaxel are semisynthetic derivatives originally isolated from Taxus species. These agents stabilize microtubules rather than blocking ion channels and are used clinically for antineoplastic effects. This contrast underscores the distinct and hazardous nature of crude yew alkaloids relative to the derived pharmaceutical agents.

Pharmacological Actions

Strong cardiotoxic effects via blockade of sodium and calcium ion channels in cardiac myocytes.
Negative chronotropic and inotropic effects causing bradycardia and hypotension.
Induction of ventricular tachycardia, fibrillation, and conduction abnormalities resistant to pharmacologic treatment.
Gastrointestinal irritant causing nausea, vomiting, and abdominal cramping.
Central nervous system effects including dizziness, mydriasis, and seizures.
Potential immunologic hypersensitivity reactions with cross-sensitivity noted to chemotherapeutic taxanes.
Toxic alkaloids exhibit resistance to standard antiarrhythmic and supportive treatments.
Limited antibacterial activity demonstrated by secondary metabolites from endophytic bacteria associated with yew.
No approved pharmacologic or therapeutic uses due to toxicity profile.
Alkaloids produce fatal cardiotoxicity in humans and animals after ingestion of plant parts.
Histamine-mediated rash and cyanotic skin changes have been observed during poisoning.
Taxane alkaloids interfere with cardiac ion channel function leading to sudden cardiac death.

Therapeutic Or Clinical Uses

Currently no approved clinical uses due to high toxicity of crude plant material.
The semisynthetic taxane chemotherapy agent docetaxel, originally extracted from Taxus baccata needles, is used in oncology but is distinct from crude yew ingestion.
Historical use of yew alkaloid taxine as an antispasmodic in folk medicine (not clinically recommended).
Research into antibacterial properties of secondary metabolites from endophytic bacteria within Taxus brevifolia.
Limited experimental interest in anticancer agents derived from Taxus species.
No use in pregnancy, lactation, or pediatric populations due to toxicity and lack of safety data.
No recommended therapeutic indications; exposure generally considered toxic or poisonous.
Investigations into potential adjunctive treatments for taxine poisoning ongoing, but no standard therapies established.

Side Or Adverse Effects

Severe cardiotoxicity including bradycardia, hypotension, ventricular tachycardia, and fibrillation.
Central nervous system effects such as dizziness, mydriasis, seizures, and coma.
Gastrointestinal symptoms including nausea, vomiting, abdominal cramping, and dry mouth.
Cutaneous reactions including rash, pale and cyanotic skin.
Cross-sensitivity hypersensitivity reactions in patients allergic to chemotherapeutic taxanes (docetaxel, paclitaxel).
Respiratory failure secondary to cardiogenic shock.
Potential fatal outcome due to cardiac or respiratory arrest.
Thrombocytopenia reported after ingestion of Chinese yew tea and extracts from related species.
Neurological impairment secondary to hypoxia resulting from cardiac arrest in poisoning cases.
Sudden death following ingestion of yew leaves or preparations, often resistant to antiarrhythmic treatment.
Arrhythmias are often refractory to pharmacologic and supportive interventions.
Potential for prolonged cardiogenic shock requiring mechanical cardiac support.
Increased susceptibility to poisoning in individuals with pre-existing heart conditions.

Precautions

Avoid ingestion or use of crude yew plant materials due to high cardiotoxic risk.
Use contraindicated during pregnancy and lactation due to embryo-fetal toxicity and alkaloid excretion in milk.
Special caution advised in psychiatric patients and persons at risk of suicide due to toxicity and lethality.
Avoid use in pediatric patients and individuals under 2 years of age due to insufficient safety data.
Patients with known allergies to taxanes, such as docetaxel or paclitaxel, should avoid exposure to yew.
Strictly avoid self-medication or preparations containing yew leaves, needles, bark, or extracts.
In cases of suspected ingestion, immediate medical evaluation and intensive supportive care are critical.
Avoid use in patients with pre-existing cardiac conduction abnormalities or arrhythmias.
Consider potential interactions with other cardiotoxic substances or drugs affecting ion channels.
Breastfeeding women should avoid exposure to yew due to alkaloid transfer through milk.
Inform healthcare professionals of any yew exposure to guide appropriate toxicology management.
Educate patients and caregivers on the dangers of yew plant ingestion and potential lethal effects.

Warnings

Yew plant parts (except red aril) are highly toxic and potentially fatal if ingested.
No safe or approved clinical use of crude yew preparations due to cardiotoxic taxane alkaloids.
Lethal doses for humans are low; ingestion of 50 grams of yew needles can be fatal.
Symptoms of poisoning appear rapidly and progress to life-threatening cardiac arrhythmias.
Standard antiarrhythmic drugs and supportive care may be ineffective against taxine-induced cardiotoxicity.
Cross-allergic reactions with taxane chemotherapeutic agents documented; risk of hypersensitivity.
Pregnant and lactating women should not use or be exposed to yew due to fetal and neonatal risk.
Children and vulnerable populations have increased risk and lack of safety data.
Emergency treatment may require advanced cardiac support including pacemaker, mechanical circulatory support, and extracorporeal life support.
Long-term neurological or organ damage can occur if not promptly and effectively treated.
Consumption of teas or preparations containing Taxus species may cause thrombocytopenia and other hematologic toxicities.
Yew poisoning should be managed as a medical emergency with aggressive supportive care.
Avoid co-exposure with other agents affecting cardiac conduction or ion channel function.

Contraindication

Use of yew plant materials is contraindicated due to inherent toxicity and lack of therapeutic indications.
Pregnancy and lactation due to embryo-fetal toxicity and alkaloid excretion in milk.
Known hypersensitivity or allergy to taxane-related compounds including docetaxel and paclitaxel.
Pre-existing severe cardiac conduction disturbances or arrhythmias due to increased risk of exacerbation.
Pediatric use contraindicated due to insufficient safety data and risk of fatal poisoning.
Avoid in patients with bleeding disorders or coagulopathy given potential for hematologic toxicity.
Use contraindicated in individuals at risk for suicide or self-harm due to lethality of ingestion.
Contraindicated in patients with severe hepatic or renal impairment where detoxification may be compromised.
No licensed pharmaceutical indications supporting use of crude yew products under any condition.
Contraindicated in combination with other cardiotoxic drugs or substances affecting ion channel function.

Drug Interactions

No formal drug interaction studies have been conducted due to the toxicity of yew plant materials.
Potential synergistic cardiotoxicity with other drugs that affect cardiac ion channels or conduction (e.g., antiarrhythmics, digoxin).
Possible cross-reactivity and hypersensitivity with chemotherapeutic taxanes such as docetaxel and paclitaxel.
Concomitant use with other cardiodepressant agents (e.g., beta-blockers, calcium channel blockers) may exacerbate bradycardia and hypotension.
No data on interaction with cytochrome P450 metabolized drugs; caution warranted due to possible metabolic pathway overlap.
Potential interference with anticoagulants and antiplatelet drugs cannot be excluded given hematologic toxicity reports.
Ingestion with other toxic plants or substances may compound toxic effects, increasing risk of fatal outcomes.
No recognized antidotal or pharmacologic agents proven to reverse yew toxicity besides supportive care and digoxin-specific antibody fragments experimentally.
Use of herbal supplements containing Taxus species should be avoided to prevent inadvertent interactions or toxicity.
Caution advised when combining with medications that prolong QT interval or induce arrhythmia.
Potential interaction with drugs affecting renal or hepatic elimination pathways of alkaloids remains unknown.
No published safety data on co-administration with common prescription or over-the-counter medications.

Preparations Of The Drug

No approved or standardized pharmaceutical preparations of yew plant material due to inherent toxicity.
Crude plant parts including needles, bark, leaves, and seeds contain toxic taxane alkaloids and are not safe for therapeutic use.
Semisynthetic taxane chemotherapy agents (e.g., docetaxel) are derived from yew but represent purified and chemically modified products distinct from the raw plant.
Traditional or folk use of yew sap and alkaloids documented historically but not clinically endorsed due to toxicity.
Extracts or teas prepared from yew leaves or bark pose significant poisoning risks and should be avoided.
Secondary bioactive metabolites isolated from endophytic bacteria in yew have demonstrated antibacterial activity in experimental settings.
No commercial dietary supplements or herbal products recognized as safe or effective containing raw yew materials.
Preparation for clinical or toxicologic assessment requires specialized extraction and quantification of taxine alkaloids.
Use of digoxin-specific Fab antibody fragments reported as an emergency intervention in toxic ingestions, but not a preparation of yew.
No veterinary formulations approved; poisoning in animals documented following ingestion of yew plant parts.
Handling precautions recommended to avoid accidental poisoning during harvesting or ornamental use.